A Three-Hour Elizabeth Holmes Documentary Just Made $15 Million — the Second-Biggest Non-Music Doc Opening Ever

LOS ANGELES · SUNDAY, OCTOBER 18, 2026

A three-hour documentary about a convicted fraudster, playing in fewer than 900 theaters, with no franchise, no stars in costume and no explosions, just made $15 million in a weekend. A24's "You Can See Everything," directed by Nathan Fielder and Lance Oppenheim, opened to an estimated $15 million domestically from only 855 theaters, according to Barron's — good for No. 2 for the weekend and, by the measure that matters for documentaries, a near-record: the second-biggest opening ever for a non-music documentary, behind only Michael Moore's "Fahrenheit 9/11," which opened to $23.9 million in 2004, per Rentrak figures cited by Barron's. The per-theater math tells the story even better: roughly $17,544 per theater, a number most wide-release blockbusters would happily frame and hang on the wall.

Context makes it bigger. USA Today reported that, discounting music documentaries, this is the second-biggest documentary debut on record — and offered the comparison that clarifies the scale: "Melania" opened to $7.1 million earlier this year, meaning the Holmes film more than doubled a heavily promoted political documentary while playing a fraction of the screens such releases usually command. A24 reported more than 2,000 sellout screenings across the weekend. About 70 percent of moviegoers were under 35, more than 90 percent said they would recommend the film, and it arrived carrying a 99 percent critics score and a 98 percent audience score on Rotten Tomatoes. Documentaries are not supposed to do this. Three-hour documentaries about white-collar crime are really not supposed to do this.

What the film actually is

The subject is Elizabeth Holmes, founder of Theranos, the blood-testing company that claimed it could run hundreds of tests from a finger-prick of blood, raised a fortune on that claim, and dissolved in 2018 after the claim collapsed. The film follows Holmes during the 34 days before she reported to federal prison in 2023 to begin serving her sentence for Theranos fraud. She is scheduled for release in 2030. That structure — a countdown, filmed at close range, with a subject who knows exactly where she is going and when — is the engine of the thing. Fielder, whose whole career is an experiment in what happens when a camera refuses to blink first, and Oppenheim, who made "Some Kind of Heaven" and knows how to find the strange tenderness inside American delusion, spent that final month of freedom watching a woman who built an empire on a story try to tell one more.

The film's path to theaters was as unusual as its subject. It premiered as a secret screening at the Telluride Film Festival on September 6, 2026 — audiences did not know what they were about to see — and was released in the United States on October 16. It runs 174 minutes and was made for a budget of roughly $7 million, according to the film's production data. Do that arithmetic and the opening weekend alone returned more than double the production budget, before a single dollar of expansion, international release or streaming value. For A24, which has turned counter-programming into a house style, this is the purest version of the trick yet: make something singular for a sane amount of money, let word of mouth do the marketing, and watch a "small" movie behave like an event.

Second place, first in the conversation

Officially, the weekend belonged to someone else: "Street Fighter" won it at No. 1 with $31 million, a result we covered earlier today. But Rentrak analyst Paul Dergarabedian, quoted by Barron's, said it in the sentence that will follow this film around: "Sometimes the biggest story at the box office isn't necessarily the movie that finishes at No. 1." He is right, and the per-theater average is why. "Street Fighter" played more than four times as many theaters. "You Can See Everything" turned 855 rooms into sellouts — more than 2,000 of them, per A24 — with a running time that limits how many showtimes a theater can even fit in a day. Every screening that sells out at 174 minutes is a screening a theater cannot turn over quickly. Exhibitors know this, which is why the expansion conversation around this film will be loud this week.

Parade, summarizing Forbes reporting, likewise called the opening a staggering result for a nearly three-hour film in a limited release, and noted how thoroughly it beat expectations for the genre. That genre context deserves one more beat. The documentary theatrical business has spent a decade being pronounced dead — absorbed by streaming, reduced to music films and nature spectacles as the only reliable big-screen draws. A non-music documentary had not opened anywhere near this level since 2004. The audience that showed up was not the traditional documentary crowd, either: with 70 percent under 35, this was the generation that grew up on the Theranos story as podcast-and-miniseries folklore, turning out in person, at full price, to sit in the dark for three hours with the real person at the center of it. There is a lesson in there for every studio that assumes young audiences will not leave the house for nonfiction.

Why Holmes, why now

Part of the answer is that Holmes remains a uniquely American character: the founder who did not just exaggerate a product but performed an entire identity — the voice, the black turtleneck, the unblinking certainty — so completely that the performance became the product. Every previous telling kept a layer between the audience and her: actors, narration, investigation. This film removes the layer and adds a clock. Thirty-four days of freedom, counted down on screen, with prison waiting at the end of it, is a structure no scripted version could improve on. The near-unanimous reviews — 99 percent from critics, 98 percent from audiences — suggest the film earns its length rather than merely imposing it, and a 90-plus percent recommend rate is the kind of number that turns a strong opening into a long run.

It also helped that the rest of the weekend gave it room to be the story. Down the chart, Whalefall opened to $8 million with its own survival-thriller hook — a perfectly respectable result that, in any normal week, would be the indie conversation. This was not a normal week. The estimates are still just that — estimates, with final numbers due as the weekend closes — and documentaries can be front-loaded when curiosity is the fuel. But even if "You Can See Everything" cools from here, it has already done the thing the industry keeps saying cannot be done: it made a three-hour documentary about a disgraced founder into the movie people felt they had to see before everyone else spoiled it for them. For more box office and entertainment coverage, see Previously's news section.